Table 2

Comparison of HRs obtained applying two analytic models (standard analysis vs GM) by settings

Chronic kidney disease settingOncology setting
Standard analysisGM analysisStandard analysisGM analysis
Biosimilars vs epoetin α originatorBiosimilars vs epoetin α originatorBiosimilars vs epoetin α originatorBiosimilars vs epoetin α originator
HR_adjLCI95%UCI95%HR_GMLCI95%UCI95%HR_adjLCI95%UCI95%HR_GMLCI95%UCI95%
Composite outcome1.020.781.330.850.601.20Composite outcome0.910.791.060.850.711.01
All-cause mortality0.920.671.280.700.471.06All-cause mortality0.820.700.970.760.620.93
Blood transfusion0.950.541.691.110.502.48Blood transfusion1.060.821.351.100.801.51
MACE0.920.491.700.950.412.19MACE0.840.481.470.900.441.82
Blood dyscrasia1.190.741.921.190.612.35Blood dyscrasia0.860.661.140.830.591.16
Biosimilars vs other originatorsBiosimilars vs other originatorsBiosimilars vs other originatorsBiosimilars vs other originators
HR_adjLCI95%UCI95%HR_GMLCI95%UCI95%HR_adjLCI95%UCI95%HR_GMLCI95%UCI95%
Composite outcome1.090.851.411.250.861.82Composite outcome1.010.881.160.960.801.15
All-cause mortality1.000.731.381.190.751.88All-cause mortality1.010.861.180.950.771,17
Blood transfusion0.990.571.710.810.391.68Blood transfusion0.980.771.230.960.711,31
MACE1.080.601.971.650.644.26MACE0.790.461.350.710.371,38
Blood dyscrasia1.260.801.991.130.592.18Blood dyscrasia0.860.661.120.820.591,14
  • adj, adjusted; GM, genetic matched; LCI, lower CI value; MACE,major cardiovascular events; UCI, upper CI value.